JPMorgan analyst Jessica Fye downgraded RayzeBio to Neutral from Overweight with a price target of $62.50, up from $30, after, after Bristol Myers-Squibb (BMY) agreed to acquire the company for $62.50 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RYZB:
- RayzeBio downgraded to Market Perform from Outperform at William Blair
- M & A News: Bristol-Myers Squibb (NYSE:BMY) to Buy RayzeBio for $4.1B
- RayzeBio jumps 99% to $60.96 after Bristol Myers takeover deal
- Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
- Bristol Myers to acquire RayzeBio for $62.50 per share in cash